There were 651 press releases posted in the last 24 hours and 170,669 in the last 365 days.

First-in-class antibiotic is safe in rats

PERTH, WESTERN AUSTRALIA, AUSTRALIA, January 17, 2019 /EINPresswire.com/ -- A scientific paper published in the journal, Scientific Reports, has shown Ramizol® a first-in-class stilbene-based investigational antibiotic for the treatment of CDI is safe in rats. The objective of the study was to evaluate the potential general toxicity in male and female rats that may arise from repeated exposure of Ramizol® for 14 days at doses of 50 mg/kg, 500 mg/kg and 1500 mg/kg administered orally.

The research, which was undertaken jointly by Boulos & Cooper Pharmaceuticals, US-based Product Safety Labs and ToxStrategies Inc., and Flinders University, has shown no mortalities in this study and no-Ramizol®-related clinical observations or side-effects. Additionally, there were no changes in mean body weight, body weight gain, food consumption or food efficiency in male and female rats attributed to the intake of the drug.

Chief Executive Officer of Boulos & Cooper Pharmaceuticals, Dr Ramiz Boulos, said "We are extremely pleased with these results for two reason. Firstly, we were able to dose rats at a very high dose, equivalent to 150 mg/mL. This level of solubility provides Ramizol® with an edge over its competition where solubility does not limit the need to administer high doses to target drug resistant bacteria. Secondly, the high level of tolerance of Ramizol® in rats has de-risked the development of this asset significantly for our first-in-man clinical trials and has given us the confidence to pursue its development”.

Ramiz Boulos
Boulos & Cooper Pharmaceuticals Pty Ltd
+61 431 150 538
email us here
Visit us on social media:
LinkedIn


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.